29 completed, 3 unknown, 2 terminated, 1 withdrawn. 12 Phase 3, 7 Phase 4, 3 Not applicable, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 11, Terminated 1 |
| Phase 4 | 7 | Completed 5, Unknown 2 |
| Not applicable | 3 | Completed 3 |
| Phase 2 | 3 | Completed 2, Terminated 1 |
Follow Sulfonylurea: new trials by email Literature Review of Sulfonylurea trials Research Report on Sulfonylurea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor - Type 2 Diabetes, Cardiac Disease | Completed | Mayo Clinic | 386301 | 2021-12-01 | 2025-10-10 | |
| Clinical Outcomes and Healthcare Cost and Resource Utilization (HCRU) in Patients With Type 2 Diabetes and Cardiovascular Disease on 2nd Line Empagliflozin Versus 2nd Line Sulfonylureas empagliflozin, metformin, sulfonylurea - Diabetes Mellitus, Type 2, Cardiovascular Diseases | Withdrawn | Boehringer Ingelheim | 2021-11-01 | 2022-06-01 | ||
| Study of Sulphonylurea Synergy With DPP4 Inhibitors Sulfonylurea, DPP4 Inhibitor - Type 2 Diabetes | Not applicable | Completed | University of Dundee | 30 | 2019-10-08 | 2021-03-04 |
| Comparative Effectiveness of Metformin for Type 2 Diabetes With Chronic Kidney Disease Metformin, Sulfonylurea, DPP-4 inhibitor - Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic | Completed | Weill Medical College of Cornell University | 4888 | 2019-08-01 | 2023-11-09 | |
| Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) Sulfonylurea - Permanent Neonatal Diabetes Mellitus | Phase 4 | Unknown | Haukeland University Hospital | 30 | 2019-02-15 | 2020-02-12 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea sotagliflozin (SAR439954), placebo, metformin - Type 2 Diabetes Mellitus | Phase 3 | Terminated | Sanofi | 377 | 2018-11-30 | 2022-04-25 |
| Replication of the CARMELINA Diabetes Trial in Healthcare Claims Linagliptin, Sulfonylurea - Diabetes | Completed | Brigham and Women's Hospital | 101830 | 2017-09-22 | 2023-07-27 | |
| Replication of the SAVOR-TIMI Diabetes Trial in Healthcare Claims Saxagliptin, Sulfonylurea - Diabetes | Completed | Brigham and Women's Hospital | 182126 | 2017-09-22 | 2023-08-01 | |
| Replication of the TECOS Diabetes Trial in Healthcare Claims Sitagliptin, Sulfonylurea - Diabetes | Completed | Brigham and Women's Hospital | 349476 | 2017-09-22 | 2023-07-27 | |
| Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes Sulfonylurea - Maturity-Onset Diabetes of the Young, Type 3, Maturity Onset Diabetes of the Young, Type 1 | Phase 4 | Unknown | Haukeland University Hospital | 30 | 2017-04-18 | 2020-01-27 |
| Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin Sotagliflozin (SAR439954), Placebo, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Lexicon Pharmaceuticals | 507 | 2017-02-24 | 2021-05-11 |
| Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan Lixisenatide (AVE0010), Sulfonylurea, metformin - Diabetes Mellitus, Type 2 | Phase 4 | Completed | Sanofi | 184 | 2017-02-23 | 2022-04-25 |
| A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey INSULIN GLARGINE (U300), metformin, sulfonylurea - Type 2 Diabetes Mellitus | Phase 4 | Completed | Sanofi | 112 | 2016-11-30 | 2019-01-14 |
| Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Sulfonylurea - Neurodevelopmental Disorders, Intellectual Disability | Unknown | Royal Devon and Exeter NHS Foundation Trust | 21 | 2016-07-01 | 2024-06-13 | |
| Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea - Type 2 Diabetes Mellitus, Proteinuria | Phase 4 | Completed | Changhua Christian Hospital | 101 | 2016-03-01 | 2019-06-14 |
| Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes Sulfonylurea - Permanent Neonatal Diabetes Mellitus | Phase 4 | Completed | Haukeland University Hospital | 90 | 2015-12-01 | 2017-10-03 |
| A Study to Assess the Addition of Sitagliptin to Metformin Compared With the Addition of Dapagliflozin to Metformin in Participants With Type 2 Diabetes Mellitus (T2DM) and Mild Renal Impairment Who Have Inadequate Glycemic Control on Metformin With or Without a Sulfonylurea (MK-0431-838) Sitagliptin, Dapagliflozin, Metformin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Merck Sharp & Dohme LLC | 614 | 2015-10-20 | 2018-11-20 |
| A Study of LY2409021 in Participants With Type 2 Diabetes Mellitus LY2409021, Sitagliptin, Placebo - Diabetes Mellitus, Type 2 | Phase 2 | Terminated | Eli Lilly and Company | 174 | 2014-04-01 | 2019-10-09 |
| Efficacy of Pioglitazone in Participants With Inadequately Controlled Type 2 Diabetes Mellitus Treated With Stable Triple Oral Therapy Pioglitazone, Metformin, Sulfonylurea - Type II Diabetes Mellitus | Phase 4 | Completed | Takeda | 114 | 2013-12-16 | 2018-09-12 |
| A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus Albiglutide, Sulfonylurea, Biguanide - Diabetes Mellitus | Phase 3 | Completed | GlaxoSmithKline | 374 | 2013-02-23 | 2017-05-03 |
Showing 20 of 35. Sign in to see all of them.
Diabetes Mellitus, Type 2 (25) · Diabetes Mellitus (10) · Cardiovascular Diseases (2) · Diabetes Mellitus, Permanent Neonatal (2) · Hyperglycemia (2) · Attention Deficit Disorder with Hyperactivity (1) · Autism Spectrum Disorder (1) · Diabetes Mellitus, Type 1 (1) · Diabetes, Gestational (1) · Epilepsy (1) · Heart Diseases (1) · Insulin Resistance (1) · Intellectual Disability (1) · Learning Disabilities (1) · Maturity-Onset Diabetes of the Young, Type 1 (1)
Sanofi (6) · Merck Sharp & Dohme LLC (5) · Brigham and Women's Hospital (3) · Haukeland University Hospital (3) · GlaxoSmithKline (2) · Royal Devon and Exeter NHS Foundation Trust (2) · Astellas Pharma Inc (1) · Boehringer Ingelheim (1) · Changhua Christian Hospital (1) · Eli Lilly and Company (1) · Janssen Research & Development, LLC (1) · Lexicon Pharmaceuticals (1) · Mayo Clinic (1) · Novo Nordisk A/S (1) · PhaseBio Pharmaceuticals Inc. (1)
United States (13) · Japan (5) · Norway (5) · South Korea (5) · Bulgaria (4) · Romania (4) · United Kingdom (4) · Denmark (3) · Germany (3) · India (3) · Israel (3) · Poland (3) · Russia (3) · Slovakia (3) · Taiwan (3)
Shirley Wang, PhD, ScM (3) · Alvin Mushlin (1) · Andrew T Hattersley (1) · Ewan R Pearson (1) · Kasper Aaboe, M.D. (1) · Lisa E Moore, MD (1) · Prof Andrew Hattersley (1)
PMID 33327727, PMID 16885550, PMID 27252787, PMID 37435938, PMID 38770818, PMID 11372010, PMID 15115830, PMID 15448106, PMID 16885549, PMID 18025408, PMID 20027034, PMID 20380655, PMID 21209033, PMID 21450987, PMID 21562320, PMID 22564709, PMID 22738801, PMID 23010561, PMID 23850055, PMID 24517339, PMID 24639432, PMID 24650952, PMID 24823514, PMID 24843595, PMID 25205142, PMID 25504028, PMID 25524432, PMID 25976701, PMID 26039935, PMID 26579834, PMID 26580237, PMID 26984361, PMID 27002421, PMID 27267268, PMID 27319011, PMID 27495291, PMID 27600862, PMID 27852119, PMID 27977934, PMID 28191913, PMID 29452178, PMID 29880308, PMID 30019498, PMID 31001673, PMID 31606880, PMID 31932458, PMID 31956422, PMID 32302665, PMID 33184150, PMID 37798422
2009 (1), 2014 (1), 2016 (1)